How might treatment of ALK-positive non-small cell lung cancer change in the near future?

Expert Rev Anticancer Ther. 2016 Oct;16(10):997-9. doi: 10.1080/14737140.2016.1226138. Epub 2016 Aug 25.

Authors

Giulio Metro¹, Guido Bellezza², Francesco Puma³, Rita Chiari¹

Affiliations

¹ a Medical Oncology , Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia , Italy.
² b Department of Experimental Medicine, Division of Pathology and Histology , University of Perugia Medical School , Perugia , Italy.
³ c Department of Thoracic Surgery , Santa Maria della Misericordia Hospital, University of Perugia Medical School , Perugia , Italy.

PMID: 27534579
DOI: 10.1080/14737140.2016.1226138

No abstract available

Keywords: ALK; ALK-TKI; Alectinib; central nervous system metastases; ceritinib; crizotinib; lorlatinib; non-small cell lung cancer.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Anaplastic Lymphoma Kinase
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / pharmacology
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Drug Design
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / pharmacology
Receptor Protein-Tyrosine Kinases / genetics*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases